Zymeworks Achieves Key Milestone with BLA Acceptance for Zanidatamab in China, Zymeworks to Receive Up to $164M in Milestone Payments
Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today
